Arizona Patent of the Month – January 2023
In today’s world of medical advancements, it’s crucial to find new and better ways to fight cancer. NuvOx Pharma LLC, a leading pharmaceutical company, has done just that by combining oxygen therapy with repeated administration of chemotherapy medications and/or radiation therapy. The use of oxygen as a radiosensitizer has been shown to increase the effectiveness of radiation therapy by making tumor cells more sensitive to the treatment.
In traditional radiotherapy, one of the biggest limitations is that tumor cells can become oxygen deficient, resulting in a hypoxic state. When in a hypoxic environment, tumor cells become up to three times more resistant to radiation damage than those in a normal oxygen environment.
Oxygen is a potent radiosensitizer – a compound that makes tumor cells more sensitive to radiation therapy. The oxygen aids in forming DNA-damaging free radicals. By incorporating oxygen therapy into the treatment plan, NuvOx Pharma is able to effectively combat hypoxia and enhance the effectiveness of radiation therapy. This innovative approach has the potential to revolutionize the way we treat cancer and improve patient outcomes.
NuvOx Pharma is a clinical stage biotechnology company developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role. Alongside this patent, the company is developing a drug which improves the flow of oxygen from lungs to blood and from blood to tissue. The company has completed over 30 animal studies, showing the therapeutic effect of their treatment in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy, and the company is preparing to run a trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF).
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
